Approved in line with NICE for:

• castration-resistant metastatic prostate cancer 
• Approved for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated in line with NICE and NHS England Commissioning Policy
• treating newly diagnosed high-risk hormone‑sensitive metastatic prostate cancer

• 60mg tablets
• Approved for treating hormone‑relapsed non‑metastatic prostate cancer that is at high risk of metastasising in adults in line with NICE
• Approved for treating hormone-sensitive metastatic prostate cancer in adults in line with NICE, only if:
  
  • docetaxel is not suitable

Initiate with specialist advice.

300mg tablets

Approved in line with NICE for

• treating hormone-relapsed prostate cancer in adults at high risk of developing metastatic disease 
• with androgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancer in line with NICE and NHSE Specialised Commissioning guidance
• with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer

• Approved for use in adults with metastatic hormone-relapsed prostate cancer, who have not had chemotherapy in line with NICE.
• Approved for treating hormone-sensitive metastatic prostate cancer in line with NICE